Search Within

Eric J Sherman

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (15)
  3. Guidelines (1)
Groups
  1. Department of Medicine (38)
  2. GSK Faculty (38)
  3. Head and Neck Service (38)
  4. Human Oncology and Pathogenesis Program (38)
  5. Solid Tumor Oncology Division (38)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (36)

More Groups

People
  1. James Fagin (35)
  2. Ronald Ghossein (21)
  3. Alan Ho (20)
  4. Robert Tuttle (19)
  5. David Pfister (15)
  6. Mona Sabra (11)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (9)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Thyroid (5)
  3. International Journal of Radiation Oncology, Biology, Physics (3)
  4. Annals of Oncology (2)
  5. Cancer (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (5)
  3. Mary Ann Liebert, Inc (5)
  4. Wiley Blackwell (4)
  5. Elsevier Inc. (3)
  6. Nature Publishing Group (3)

More Publishers

Results (38)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term results of external beam radiation therapy with or without concurrent chemotherapy in differentiated thyroid cancer
    Journal Article

    Choi, J.; Sherman, E.; Dee, E. C.; Treechairusame, T.; Zakeri, K.; Kang, J. J.; Yu, Y.; Chen, L.; Shamseddine, A.; McBride, S. M.; more...
    Thyroid (2025)

    Fulltext@MSK | Save
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial
    Journal Article

    Vos, J. L.; Burman, B.; Jain, S.; Fitzgerald, C. W. R.; Sherman, E. J.; Dunn, L. A.; Fetten, J. V.; Michel, L. S.; Kriplani, A.; Ng, K. K.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer
    Meeting Abstract

    Abdelhamid Ahmed, A. H.; Russell, M. D.; Kyriazidis, N.; Silver Karcioglu, A.; Sherman, E. J.; Ho, A. L.; Fagin, J. A.; Wong, R. J.; Busaidy, N. L.; Zafereo, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase
    Journal Article

    Boucai, L.; Salas-Lucia, F.; Krishnamoorthy, G. P.; Sherman, E.; Rudin, C. M.; Drilon, A.; Bianco, A. C.; Fagin, J. A.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer
    Journal Article

    Lee, N. Y.; Riaz, N.; Wu, V.; Brinkman, T.; Tsai, C. J.; Zhi, W.; Fetten, J.; Ho, A.; Wong, R. J.; Ghossein, R.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
    Guidelines

    Shonka, D. C. Jr; Ho, A.; Chintakuntlawar, A. V.; Geiger, J. L.; Park, J. C.; Seetharamu, N.; Jasim, S.; Abdelhamid Ahmed, A. H.; Bible, K. C.; Brose, M. S.; more...
    Head & Neck (2022)

    Fulltext@MSK | Save
  • Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ERBB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial
    Journal Article

    Tchekmedyian, V.; Dunn, L.; Sherman, E.; Baxi, S. S.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
    Journal Article

    Rosen, E. Y.; Won, H. H.; Zheng, Y.; Cocco, E.; Selcuklu, D.; Gong, Y.; Friedman, N. D.; de Bruijn, I.; Sumer, O.; Bielski, C. M.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save